Pharmafile Logo
Pharmafocus logo
Advanced Search

Biogen

Showing 15 posts of 112 posts found.

Google image

J&J and Google partner to build surgical robots

March 30, 2015
Medical Communications, Sales and Marketing Biogen, Ethicon, J&J, JJ, Johnson and Johnson, MS, google, robots

The medical device subsidiary of Johnson & Johnson Ethicon is to collaborate with Google to build surgical robots and perform …

News
Genome image

Big pharma teams with government on genomic research

March 27, 2015
Research and Development, Sales and Marketing AbbVie, Alexion Pharmaceuticals, AstraZeneca, Biogen, Cameron, Dimension Therapeutics, GSK, Genomic, Genomics england, Helomics, Roche, Takeda, UCB, UK, genomes

Ten firms will partner up with Genomics England to develop new diagnostics and treatments for people with rare diseases and …

News
Biogen image

Biogen shortens name and posts positive Alzheimer’s results

March 23, 2015
Sales and Marketing AD, Alzheimer's, BIIB037, Biogen, MS, Parkinson's, aducanumab, idec

Biogen Idec is to be known only as Biogen hence forth as the US biotech also reveals positive early results …

News
Google image

Google partners with Biogen on multiple sclerosis

January 30, 2015
Medical Communications, Sales and Marketing Biogen, MS, calico, conrad, google, google x, scangos

Google is making further headway into healthcare by teaming up with Biogen Idec in order to study what leads to …

News
Biogen image

EMA review for Biogen Idec’s haemophilia A therapy

November 4, 2014
Sales and Marketing Biogen, elocta, eloctate, haemophilia a, idec, sobi

The EMA is set to review Biogen Idec and Sobi’s haemophilia A therapy Elocta after validating the drug’s marketing authorisation …

News
Biogen Idec logo

NICE final ‘yes’ for Biogen’s MS pill

August 27, 2014
Sales and Marketing Aubagio, Biogen, RMS, RRMS, gilenya

In final guidance published today NICE has recommended NHS funding of Biogen Idec’s new multiple sclerosis pill in patients with …

News
Biogen image

FDA approves Biogen’s long-acting MS drug

August 18, 2014
Sales and Marketing Avonex, Biogen, FDA, MS, Rebif, plegridy, tecfidera

Biogen Idec has racked up another approval over the weekend after its latest multiple sclerosis treatment Plegridy gained FDA backing. …

News
biogen_austria_238

Biogen gets CHMP thumbs up

May 27, 2014
Sales and Marketing Biogen, CHMP, Gazyvaro (obinutuzumab), Nuwiq, Octapharma, Orphan, Roche, chronic lymphocytic leukaemia, plegridy

Biogen Idec is celebrating after the Committee for Medicinal Products for Human Use (CHMP) gave its multiple sclerosis drug Plegridy …

News
screen_shot_2014-01-29_at_10

High-dose Copaxone the right medicine for Teva

January 29, 2014
Research and Development, Sales and Marketing Biogen, Copaxone, FDA, MS, Mylan, Teva

The FDA has approved a high-dose version of Teva’s multiple sclerosis drug Copaxone which will help the firm offset approaching …

News
FDA image

US nod for Tecfidera

March 28, 2013
Sales and Marketing Biogen, FDA, tecfidera

The FDA has given Biogen Idec’s oral multiple sclerosis treatment Tecfidera the green light. Earlier this week Tecfidera (dimethyl fumarate) …

News
Roche image

Facility of the year: 2013 winners announced

February 4, 2013
Manufacturing and Production Biogen, MedImmune, Merck, Novartis, Roche

Three US and three European manufacturing plants have been selected as category winners for the annual Facility of the Year …

News

Biogen inks $299m deal for rare genetic disorder drug

January 5, 2012
Research and Development, Sales and Marketing Biogen, Isis Pharma

Biogen has signed a new deal with drug discovery firm Isis for its spinal muscular atrophy drug ISIS-SMNRx. Biogen will pay …

News

Biogen and Samsung invest $300m on joint biosimilars venture

December 8, 2011
Manufacturing and Production Biogen, Samsung, biosimilars

Biogen Idec and Samsung will invest $300 million in a joint venture to develop biosimilars. Both firms will contribute a …

News

Biogen’s MS drug hits phase III targets

October 27, 2011
Sales and Marketing BG-12, Biogen, MS

Biogen’s potential blockbuster MS drug BG-12 has met its primary endpoint in a late-stage trial.   BG-12 (dimethyl fumarate) tablets …

News

New MS drug shows promise for Abbott

August 10, 2011
Research and Development, Sales and Marketing Abbott, Avonex, Biogen, MS, gilenya

Biogen and Abbott’s multiple sclerosis drug daclizumab has performed well in a mid-stage trial, but two deaths marred the overall …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024